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Introduction
The discovery and optimization of RNA interference (RNAi) 
technologies over the past 10 years has made it possible 
to routinely develop in vitro picomolar (pM) small interfering 
RNA (siRNA) inhibitors to any chosen gene within a matter 
of weeks.1 Significant progress has also been made, through 
the incorporation of straightforward chemical modifications, in 
introducing drug-like properties into siRNA duplexes, result-
ing in improved nuclease stability and reduced immunostimu-
latory capacity.1,2
While numerous approaches for in vivo siRNA silencing 
have been reported involving both local and systemic deliv-
ery, robust and repeated success with commercially viable 
formulations has been limited.3 Systemic delivery of siRNA 
has resulted in silencing of liver-specific genes using several 
different classes of lipid nanoparticle (LNP)-based formula-
tions. Broadly speaking, LNPs can be classified into those 
containing  cationic  or  ionizable  lipids  as  their  main  active 
component and differ in both their structure and mechanism 
of uptake.4,5 While both cationic and ionizable lipids can be 
formulated  into  LNPs  with  the  same  size  and  encapsula-
tion  properties, “ionizable”  lipids  maintain  a  nearly  neutral 
charge  at  physiological  pH  while “cationic”  lipids  have  an 
overall slightly positive charge. Recently, in vivo hepatocyte 
gene silencing has been improved by roughly two orders of 
magnitude  for  both  classes  of  LNPs  through  identification 
of  novel  lipids  and  formulation  optimization.  Early  reports 
demonstrated efficacious mRNA silencing in hepatocytes at 
siRNA doses of ~1 mg/kg6,7 and more recent reports show 
similar efficacy at doses of ~0.01 mg/kg.4,5 Importantly, not 
only has progress been made in the potency and mechanis-
tic understanding of how these LNP mediate siRNA delivery,8 
but also in the translation of this technology: multiple LNP-
siRNA therapeutic candidates are currently in clinical testing 
and late stage preclinical development.9
Despite impressive progress in siRNA delivery to hepato-
cytes, efficacious systemic siRNA delivery to extra-hepatic 
cells  and  tissues  remains  difficult.  One  area  of  particular 
interest is delivery to immune cells, given their central role 
in homeostasis and disease. siRNA delivery by an antibody 
or peptide linked to a cationic entity, such as protamine or 
poly-arginine  has  been  reported.10–13  Application  of  these 
formulations resulted in the inhibition of viral replication or 
protection  from  cytokine  induction  via  delivery  of  siRNA. 
Another approach taken by Peer and colleagues employed 
antibody-targeted lipid particles to deliver siRNA to immune 
cells  via  anti-β7  integrin  antibody14  or  anti-CD11a  anti-
bodies,11 resulting in improvement of disease in a dextran 
sodium   sulfate colitis mouse model and HIV resistance in 
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a humanized mouse model, respectively. It has also been 
reported  that  siRNA  can  be  delivered  to  macrophages 
after oral administration by packaging in yeast particles,15 
or via injection of polymer or lipoplex complexes after intra-
peritoneal  administration  in  chitosan/siRNA  particles.16,17 
Importantly however, much of the above mentioned work on 
silencing immune cell genes has used chemically unmodi-
fied  siRNA  duplexes  that  are  known  to  stimulate  innate 
immune response and could, therefore, result in nonspecific 
gene modulation.18,19
Innate  immune  cells,  in  particular  monocytes  and  mac-
rophages, are critical for inducing and orchestrating global 
and  local  immune  responses,20  and  are  centrally  involved 
in disease initiation and progression. Thus, we focused our 
attention on these cells, which are also professional phago-
cytes and therefore have the propensity to engulf nanoparti-
cle-based formulations. We developed highly active siRNAs 
to genes expressed in myeloid cells and optimized the LNP 
formulations  for  greater  potency,  achieving  half-maximal 
silencing doses of 0.2 mg/kg. Using dynamic fluorescence 
tomography  combined  with  microscopy,  we  show  robust 
delivery of siRNA to the spleen in mice. These formulations 
provide efficacious RNAi-mediated silencing of multiple tar-
gets in myeloid cells in both healthy rodents and nonhuman 
primates (NHPs). In addition, we demonstrated that by inhib-
iting the well-validated target tumor necrosis factor-α (TNFα) 
in a macrophage-dependent model of rheumatoid arthritis 
(RA), disease activity was drastically reduced to a level com-
parable with potent antibody-mediated treatment. Two very 
recent  studies  complement  and  further  extend  this  work. 
Basha et al. present a detailed analysis establishing the KC2 
ionizable lipid as very potent vehicle for siRNA delivery to 
antigen-presenting  cells.21  Leuschner  et  al.  demonstrates 
the broad therapeutic potential of C12-200-mediated deliv-
ery to myeloid cells while focusing on a specific gene target, 
CCR2.22 Taken together these findings represent a signifi-
cant advancement in both RNAi technology and drug devel-
opment as they open possibilities to simultaneously silence 
gene targets not accessible to small molecules or antibodies 
in myeloid cells, offering new therapeutic opportunities for 
diseases with inflammatory etiology.
Results
Significant work has been dedicated toward the development 
of new materials and formulations for the delivery of siRNA 
to  hepatocytes  (see  e.g.  refs.  4,5). We  sought  to  develop 
nanoparticles with delivery potential to myeloid cells through 
the use of lipids and lipid-like materials known as KC2 (an 
ionizable lipid)4 and C12-200 (a cationic lipid).5 Formulations 
containing these lipid materials, as well as the excipients: cho-
lesterol, PEG-DMG, and distearoyl phosphatidyl choline were 
formulated as nanoparticles, encapsulating siRNAs directed 
to several myeloid-expressed gene targets (including CD45, 
CD11b, integrin β1, TNFα). The KC2 containing formulations 
utilized here use a higher molar percent of cationic lipid com-
pared to earlier work,4 further increasing formulation potency. 
We also optimized the C12-200 containing liposomes increas-
ing the lipid to siRNA ratio in the particle.
Quantitative in vivo whole body imaging and histological 
localization of LNP-siRNA distribution. In order to deter-
mine LNP-siRNA distribution, we intravenously (i.v.) injected 
LNP-encapsulated,  fluorescently  labeled  siRNA,  and  fol-
lowed  whole  body  fluorescence  by  fluorescence-mediated 
tomography/X-ray computed tomography (FMT-CT). FMT-CT 
is a hybrid imaging approach that quantitates fluorochrome 
concentration in tissue, while fusion with CT data provides 
the anatomic  localization  of  the  fluorescent  signal  at  high 
resolution.23  Concentration  was  sampled  90  minutes  after 
injection of siRNA formulated in KC2 LNP and C12-200 LNP 
(Figure 1a), and key organs were then analyzed. Fluores-
cent signal reporting on siRNA concentration was attributed 
to anatomical structures using hybrid CT data. Interestingly, 
we found that the spleen is a major distribution site for both 
LNP preparations, with high fluorescence per gram of tissue 
(Figure 1a,b). Imaging also provided information about the 
excretion pathway of LNP siRNA. The signal peaked in the 
liver, gall bladder and intestine likely reflecting the excretion 
of the fluorochrome and attached materials. Low signal was 
observed in the kidneys and the urinary tract   (Figure 1 and 
data  not  shown).  Low  siRNA  concentration  was  observed 
in  the  lung  for  both  nanoparticles.  Ex  vivo  fluorescence 
reflectance  imaging  corroborated  these  findings  with  the 
spleen  showing  the  brightest  signal  among  major  organs 
(  Figure  1b,c).  Distribution  data  obtained  by  imaging  are 
consistent with plasma/tissue siRNA amount derived from 
a PCR-based method of siRNA quantification,24 which gives 
us confidence that we are not merely tracking fluorochrome, 
but fluorescently labeled siRNA. Leuschner et al. have shown 
that multiple myeloid cell types in the spleen take up C12-
200 LNP-formulated siRNA including macrophages, splenic 
reservoir monocytes, and dendritic cells.22 Similar analysis 
carried out for the KC2 formulation did not reveal major differ-
ence in the cell populations targeted (data not shown).
Efficient silencing of gene targets in myeloid cells after 
i.v. injection. Encouraged by the distribution of LNP siRNA 
to sites of immune cell localization, we initiated experiments 
to determine whether distribution translates into RNAi silenc-
ing activity in leukocytes. Macrophage lineage cells special-
ize in the removal of foreign material, thus most systemically 
administered particles are taken up by these cells. In fact, 
cells of the monocyte/macrophage lineage showed the high-
est  fluorescence  signal  after  i.v.  injection  of  fluorescently 
labeled siRNA (see below). However, uptake often does not 
translate  into  siRNA-induced  silencing;  macrophages  spe-
cialize  in  shuttling  cargo  into  lysosomes  for  degradation, 
whereas siRNA needs to reach the cytoplasm to induce cleav-
age of the target mRNA. Indeed, with earlier-  generation LNP 
formulations,6,7 despite good uptake we have not observed 
siRNA-mediated  gene  silencing  in  macrophages  after  i.v. 
administration.
To determine which leukocyte populations are subject to 
silencing in response to i.v. injected LNP-siRNA, we used a 
CD45 silencing assay. CD45 is a common, highly expressed 
leukocyte antigen that occupies up to 10% of the cell surface.25 
We  assayed  CD45  protein  knockdown  by  flow  cytometric 
analysis of leukocytes defined by combinations of specific cell 
surface markers and then measured the decrease of CD45 www.moleculartherapy.org
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expression in each of these cell populations (Figure 2). We 
compared leukocytes from animals injected with a formulation 
containing  a  CD45-specific  siRNA  versus  animals  injected 
with  an  identical  formulation  containing  a  control  siRNA 
  targeting  luciferase. We  surveyed  leukocytes  isolated  from 
different organs (spleen, liver, peritoneal cavity, bone   marrow, 
and lymph nodes) 3 days after a single i.v. bolus injection 
(Figure 2a and Supplementary Figure S1b). A 3-day inter-
val between injection and protein level analysis was needed 
to allow the reduction in mRNA levels to be translated into 
decreased  CD45  protein  expression.  Using  this  assay,  we 
found highly effective (~80%) silencing in cells of macrophage 
lineage (Figure 2a,b), good (~40%) silencing in dendritic cells 
(Supplementary Figure S1b), some activity (~15%) in B cells 
(Supplementary Figure S1c, and no silencing in T cells, NK 
cells, or GR-1+ granulocytes (Supplementary Figure S1c). 
Silencing in all cell types was examined in multiple tissues 
including spleen, liver, bone marrow, blood, and peritoneal 
cavity. These findings imply broad applicability of this technol-
ogy to diseases that involve innate immune activation, infec-
tion, and antigen presentation.
To address whether ingestion of LNPs might activate leuko-
cytes, we compared mice injected with PBS versus siRNA in 
LNP. Notably, we used only chemically modified siRNA mole-
cules (2′OMe modified at selected pyrimidine sites) which do 
not induce cytokine production in the human PBMC assay.18 
We investigated leukocyte numbers as well as their activation 
status in blood, spleen, bone marrow, and peritoneal cavity 
following an i.v. administration of LNP siRNA. Interestingly, 
we did not find evidence for overt activation in any of the 
populations surveyed; there was no increase in costimulatory 
molecules CD80 and CD86 or in MHCII expression (Supple-
mentary Figure S2). After injection of Luc LNP-siRNA, we 
observed a minor influx of CD11b− low cells in the peritoneal 
cavity and slight CD45 upregulation on CD11b+ cells (Sup-
plementary Figure S2).
To  corroborate  the  CD45  silencing  data,  we  conducted 
silencing  experiments  with  other  gene  targets,  including 
green  fluorescent  protein  (GFP),  CD11b,  integrin  β1,  and 
TNFα, where we observed similar or greater silencing effi-
ciencies (Supplementary Figure S3 and data not shown). 
For instance, silencing of integrin β1 in CD11b+ cells from 
the bone   marrow was more pronounced than that of CD45 in 
the same cells (Supplementary Figure S3). These observa-
tions may reflect both intrinsic differences in the potencies 
of the specific siRNA (half-maximal concentration required 
for in vitro silencing of 10 pM for integrin β1 versus 90 pM 
for CD45) and different characteristics in the target mRNA 
transcripts (e.g., mRNA half-life).
Interestingly, the anatomical location showing the stron-
gest silencing of CD45 after i.v. injection in mice was the 
peritoneal cavity with up to 90% reduction in CD45 protein 
expression, followed by significant silencing in the spleen, 
and only moderate silencing seen in the bone marrow, lymph 
nodes, and liver (Figure 2 and Supplementary Figure S1, 
data not shown), using shift in mean fluorescent intensity of 
the total population as the metric. It is noteworthy that within 
a population with average silencing even at 20–30%, there 
Figure 1  In vivo dynamic fluorescence-mediated tomography/X-ray computed tomography (FMT-CT) of lipid nanoparticles 
(LNP)-small interfering RNA (siRNA) delivery and siRNA localization within reservoir monocyte clusters in the spleen. (a) 3D 
reconstruction of FMT-CT data of KC2 (left) and C12-200 (right) is shown. The arrow points to the position of splenic signal. Signal in organ 
systems of interest was quantified, data are shown as mean and SE, n = 4–5 per group. (b). Ex vivo fluorescence reflectance imaging after 
injection of LNP siRNA side-by-side imaging of respective organs and highlights the signal intensity in the spleen. (c) Fluorescence images 
of spleens from mice injected or not injected with LNP-siRNA.
40,000
KC2 a
b c
C12-200
10,000
15,000
7,500
250
No injection
siRNA LNP
Spleen Spleen Lung Kidney Liver
250
F
l
u
o
r
e
s
c
e
n
c
e
 
(
p
m
o
l
/
g
)
F
l
u
o
r
e
s
c
e
n
c
e
 
(
p
m
o
l
/
g
)
G
a
l
l
 
b
l
a
d
d
e
r
S
p
l
e
e
n
L
i
v
e
r
I
n
t
e
s
t
i
n
e
S
k
e
l
e
t
a
l
 
m
u
s
c
l
e
K
i
d
n
e
y
B
l
o
o
d
 
p
o
o
l
L
u
n
g
G
a
l
l
 
b
l
a
d
d
e
r
S
p
l
e
e
n
L
i
v
e
r
I
n
t
e
s
t
i
n
e
S
k
e
l
e
t
a
l
 
m
u
s
c
l
e
K
i
d
n
e
y
B
l
o
o
d
 
p
o
o
l
L
u
n
gMolecular Therapy–Nucleic Acids
RNAi-mediated Gene Silencing in Myeloid Cells
Novobrantseva et al
4
are subpopulations of cells with silencing as high as >95% 
at the lower end of distribution. Given the extreme stability 
and abundance of CD45, it is likely a gene target that is more 
refractive to silencing.
Next,  in  dose  response  experiments,  we  assessed  the 
potency of in vivo silencing in peritoneal macrophages and 
found  that  C12-200  LNP  induced  50%  CD45  silencing  at 
doses of ~0.2 mg/kg, and KC2 LNP at doses of ~0.5 mg/kg 
(Figure 2a,b). This is a significant improvement compared 
to similarly formulated LNPs using early generation cationic   
lipids, where no silencing in leukocytes was seen after i.v. 
injection of at least tenfold higher doses.7 Even compared to 
LNPs using the KC2 lipid the formulation used here shows 
a  sixfold  improvement  in  potency  with  50%  silencing  at 
0.5 mg/  kg versus 3 mg/kg22 in peritoneal macrophages. Know-
ing that peritoneal cells are sessile, we could monitor longev-
ity of silencing in vivo using cells transferred intraperitoneally 
from the peritoneum of GFP transgenic mice. To this end, we 
injected cohorts of animals with CD45 or control LNP-siRNA 
and  sacrificed  them  at  different  time  points. We  observed 
silencing in peritoneal macrophages for up to 3 weeks after 
a single injection (Figure 2c), which is near identical to the 
duration of silencing observed in hepatocytes.4,5 We observe 
a longer silencing duration than that seen in peritoneal mac-
rophages put in culture following liposome treatment.21 This 
may be a reflection of the differences in the assay systems 
and the gene targets being assayed (CD45 versus GFP).
With such low doses, it is possible to combine several gene 
targets for silencing in leukocytes, thus, enabling functional 
genomics studies in the cells central to inflammatory disor-
ders. To validate this utility, we performed an experiment that 
mixed  siRNA  to  four  independent  gene  targets  formulated 
in C12-200 LNP, each at the 0.2 mg/kg dose, an estimated 
IC50 dose for the CD45 siRNA. We included siRNA target-
ing  CD45,  CD11b,  RAB5c,  and  integrin  β1  into  this  cock-
tail. Silencing was monitored in total peritoneal cavity cells   
24 hours post injection on the mRNA level by reverse tran-
scription-quantitative  PCR.  We  observed  silencing  ranging 
from 50 to 80% for each of the targets as compared to the 
levels seen in animals dosed with control siRNA (Figure 2d).
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Macrophage uptake of LNP-siRNA relies on phagocy-
tosis. Since both KC2 and C12-200 represent potent LNP 
formulations for myeloid cell silencing in vivo, we chose to 
investigate the mechanism of cellular uptake for these two 
formulations. We performed uptake experiments with   primary 
mouse  bone  marrow-derived  macrophages  that  were 
treated with fluorescently labeled siRNA in KC2 or   C12-200 
LNP. C12-200, relative to KC2 LNP, mediated more efficient 
uptake of the labeled siRNA by primary macrophages in vitro 
consistent with mRNA-silencing results (Figure 3a). To char-
acterize the mechanism of cellular uptake, we co-exposed 
primary macrophages to markers of different endocytic path-
ways. We saw ~60–70% colocalization of labeled siRNA par-
ticles with fluorescent latex beads that due to their large 1 µm 
size enter these cells by phagocytosis (Figure 3b,c).26 We 
saw substantially less colocalization with   markers of other 
pathways: dextran, a marker of macropinocytosis (~40%), 
and transferrin, a marker of   clathrin-mediated endocytosis 
(10%)  (Supplementary  Figure  S4a–c).  Latex  beads  and 
siRNA-containing vesicles colocalized most prominently in 
the perinuclear region; these likely represent vesicles that 
have already undergone lysosome fusion (Figure 3b). Since 
phagosomes are known to contain the EEA1 marker27 the 
compartments in which siRNA signal is observed likely cor-
respond to the EEA1 positive structures reported by Basha 
et  al.21  In  addition,  LNP-siRNA  uptake  was  inhibited  by 
Cytochalasian D and by Dynasore (inhibitors of actin rear-
rangement and dynamin, respectively, both previously shown 
to inhibit different steps of phagocytosis (Supplementary 
Figure  S4d,e)). We  therefore  concluded  that  the  primary 
mechanism of LNP siRNA internalization in macrophages 
was phagocytosis.
Silencing  of  myeloid  genes  in  vivo  occurs  in  both 
  tissue-resident and splenic reservoir cells of monocyte/
macrophage lineage. A key question for therapeutic gene 
silencing in leukocytes is whether delivery can be achieved 
to circulating and splenic monocyte/macrophages, including 
splenic reservoir monocytes that migrate in high numbers 
to inflammatory sites such as acute myocardial infarcts.28–30 
One technical challenge in assessing in vivo gene silenc-
ing in   leukocytes is their migratory nature. The site of initial 
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  LNP-siRNA uptake and the ultimate cell destination when 
protein  downregulation  is  detectable  may  not  coincide. To 
address this issue, we injected mice i.v. with LNP-siRNA and 
isolated monocytes/macrophages from bone marrow, blood, 
spleen, and peritoneal cavity at 15, 60, and 120 minutes post 
injection. The cells were then seeded onto plastic to allow 
time  for  downregulation  of  CD45  protein  expression. This 
strategy interrupted the migratory path of the cells, and deter-
mined the site of effective uptake independent of subsequent 
cell relocation. Interestingly, we did not observe any silencing 
in the bone marrow in this assay, whereas blood monocytes 
reached maximum silencing at 15 minutes, splenic cells at 
1 hour, and peritoneal macrophages at 2 hours after injec-
tion  with  KC2  LNP-formulated  CD45  siRNA  (Figure  4a). 
The maximal levels of CD45 silencing seen in this in vivo/   
in vitro assay (>50%) were comparable to the levels reached 
3 days post injection in vivo (Figure 4a). Silencing kinetics 
were  faster  following  injection  of  C12-200  LNP-formulated 
siRNA, with maximal blood silencing as early as 5 minutes 
post injection (data not shown). These data indicate that LNP 
siRNA effectively reached the central pool of circulating and 
splenic monocytes, as well as resident tissue macrophages. 
Due to the fast migratory kinetics of myeloid cells, many cir-
culating and splenic monocytes relocate to target tissue after 
ingesting LNP siRNA. Some of these transfected cells appear 
to migrate to the peritoneal cavity.
The  efficient  silencing  seen  in  mouse  peritoneal 
  macrophages 3 days after i.v. injection was surprising, and 
may be (i) a functional consequence of gene silencing, (ii) due 
to migration of the cells that had been targeted while circu-
lating in blood or residing in the spleen, and/or (iii) a result 
of local accumulation of LNP siRNA in the peritoneal cavity 
and uptake by resident macrophages. Notably, the kinetics 
of LNP accumulation in peritoneal cavity macrophages was 
  significantly  slower  than  that  observed  in  blood  or  spleen 
 ( Figure 4c,d). Using GFP-expressing transgenic mice, we 
found  that  equally  efficient  silencing  of  GFP  can  also  be 
  measured in the peritoneal cavity macrophages, therefore 
excluding a role for endogenous gene knockdown in localiza-
tion of these cells to the peritoneal cavity (Supplementary 
Figure S3a).
To determine whether LNP internalization first occurred in 
circulation or locally in the peritoneal cavity, we transferred 
resident GFP+ peritoneal cells into the peritoneum of wild-
type mice and injected recipient mice i.v. with LNP-siRNA 
targeting CD45 30 minutes after cell transfer. CD45 in both, 
GFP+ and well as GFP− cells, was silenced to a nearly identi-
cal degree in vivo (Figure 4b). This experiment established 
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that  gene  targets  in  sessile  resident  peritoneal  cells31  are 
also silenced by i.v. injected LNP-siRNA.
Silencing mRNA specific for the monocyte/macrophage 
lineage. While the CD45 assay allowed us to follow many 
leukocyte cell types in parallel, it necessitated isolation of 
leukocytes from different tissues to identify cell types by sur-
face staining. Previous work demonstrated that some tissue 
resident leukocytes cannot be isolated,32 thereby making it 
impossible to assess the degree of silencing in such cells 
by flow cytometry. We therefore decided to focus on all cells 
of  the  monocyte/macrophage  lineage  by  devising  siRNA 
against CD11b (Mac-1) and thus enabling total tissue mRNA 
analysis of silencing in the cells of interest. This siRNA was 
very active in vitro with an IC50 of about 4 pM. We identified a 
24-hour time point when mRNA for CD11b was significantly 
silenced, but cell surface protein was still unaffected, to avoid 
potential effects specific to CD11b function. We performed 
in  vivo  titration  of  LNP  encapsulated  CD11b  siRNA  and 
found it required ~0.3 mg/kg siRNA in C12-200 and ~1 mg/
kg siRNA in KC2 LNP to achieve 50% silencing at the mRNA 
level in the peritoneal cavity cells (Figure 5). These in vivo 
potencies were very similar to those found for the CD45 pro-
tein and they demonstrate the robustness and reproducibility 
of silencing across several targets, using mRNA and protein 
as readouts.
We proceeded to test CD11b silencing in different organs, 
measuring  the  ratio  of  CD11b  mRNA  level  to  GAPDH.  In 
spleen and peritoneal cavity, CD11b mRNA was reduced to 
similar levels when compared with CD45 silencing (Figures 2 
and 5 and Supplementary Figure S1), namely, ~30% in the 
spleen and 70–90% in peritoneal cavity. Interestingly, we also 
found efficient CD11b knockdown in the liver (Figure 5). We 
believe that the near absence of CD45 silencing in the mac-
rophages isolated from liver reflects the fact that a true resident 
population of Kupffer cells is not isolated by the liver digestion 
protocols employed and was therefore not accessible to flow 
cytometric  analysis.32  CD11b  knockdown  was  also  normal-
ized to another macrophage-specific marker, F4/80, and was 
shown to be very similar to the values obtained by normaliza-
tion to GAPDH (data not shown): This indicates that observed 
CD11b knockdown is not due to the loss of macrophages.
CD45 and CD11b silencing is RNAi mediated. To confirm 
that the knockdown of myeloid gene mRNA observed in rodents 
was mediated by an RNAi silencing mechanism, we isolated 
CD11b+ cells from mice treated with either CD45 or CD11b 
LNP-siRNA. mRNA from these cells was then subjected to 
rapid amplification of cDNA ends (5′-RACE), a method pre-
viously  used  to  demonstrate  siRNA-mediated  cleavage.6,33 
5′-RACE analysis of peritoneal cavity   macrophage-derived 
mRNA from animals treated with LNP-siRNA revealed prod-
ucts of the expected sizes for both CD45 and CD11b ampli-
cons in their respective cohorts (Supplementary   Figure S5). 
Sequence analysis of cloned PCR products demonstrated 
that 46 out of 48 and 24 out of 24 PCR products were derived 
from the predicted cleavage event at position (CTGGCTGAA/
TTTCAGAGCA) for CD45 siRNA in KC2 and C12-200 LNP, 
respectively; for CD11b, 29 out of 48 and 20 out of 24 PCR 
products were cleaved at position (TTGTCTCAA/CTGTGAT-
GGA) in KC2 and C12-200 LNP, correspondingly. No specific 
cleavage site PCR products were derived from the 5′-RACE 
samples treated with LNP-encapsulated control siRNA (out 
of 140 sequenced products) except for one likely contami-
nant clone with CD45 cleavage product derived from CD11b 
siRNA in C12-200 LNP treated cells. These results clearly 
demonstrate that the effect of siRNA in LNP treatment on 
CD45 and CD11b expression levels observed is due to cleav-
age of the mRNA transcript via an RNAi mechanism.
siRNA-mediated silencing in immune cells substantially 
inhibits disease progression in a mouse model of RA. 
To determine whether the effective silencing in macrophages 
translated into disease modifying activity, we tested TNFα-
specific siRNA in an antibody-induced arthritis mouse model 
in which systemic inhibition of soluble TNFα has been previ-
ously shown by several groups to be highly effective.34 Using 
siRNA targeting TNFα, we found inhibition of paw swelling in 
two independent experiments with C12-200 LNP   (Figure 6a). 
In  fact,  the  anti-inflammatory  activity  was  comparable  to 
anti-VLA1  i.v.  antibody  treatment  (Figure  6a,d),  which  has 
been previously demonstrated to be at least as effective as 
systemic TNFα inhibition.35 In agreement with the near com-
plete absence of redness and swelling in the joints and dig-
its, histological analyses of paw sections showed significantly 
decreased edema, synovial inflammation, and inflammatory 
cell infiltration in TNFα siRNA-treated animals (Figure 6d). To 
quantitate the degree of inflammation in siRNA-treated ani-
mals, we used in vivo fluorescence tomography of arthritic 
joints after injection of a pan-cathepsin sensor, which reports 
on protease activity.36 Using this method, we found that TNFα-
specific LNP siRNA reduced joint inflammation by more than 
100
%
 
C
D
1
1
b
 
s
i
l
e
n
c
i
n
g
80
60
40
20
0
100
%
 
C
D
1
1
b
 
s
i
l
e
n
c
i
n
g
80
60
40
20
0
KC2
PerC
Liver
C12-200
0.1 mg/kg
1 mg/kg
3 mg/kg
0.25 mg/kg
0.1 mg/kg
1 mg/kg
3 mg/kg
0.25 mg/kg
KC2 C12-200
Figure 5  Macrophage-specific CD11b silencing. mRNA ratio 
of CD11b to GAPDH was measured in peritoneal cavity or total 
perfused liver lobes 24 hours after bolus intravenous (i.v.) injec-
tion of small interfering RNA (siRNA) in lipid nanoparticles (LNP). 
Bars represent the mean level from three animals per group, three 
biological replicas per sample, with SEM in animals treated with 
CD11b siRNA relative to Luc siRNA-treated animals.Molecular Therapy–Nucleic Acids
RNAi-mediated Gene Silencing in Myeloid Cells
Novobrantseva et al
8
half (Figure 6c,e). In splenic macrophages from arthritic mice 
treated with TNFα targeting but not with control siRNA, we 
found  a  decrease  of  intracellular  TNFα  staining  indicating 
effective silencing (Figure 6b).Overall, the effect of treatment 
on mean fluorescent intensity value is highly significant accord-
ing to an ANOVA (F = 17.061, P < 10−5). Tukey’s   post-hoc tests 
indicate that the pairwise difference between mean MFI in the 
TNFα siRNA group and the Luc siRNA group is significant   
(P = 0.0197; see star in Figure 6b).
In  vivo  silencing  in  circulating  monocytes  in  NHPs. 
Finally, in order to determine the translational potential of 
RNAi-  mediated silencing in immune cells, we explored leu-
kocyte gene silencing in NHPs. We first performed a non-
terminal  study  in  cynomolgus  macaques  and  examined 
efficacy of a single dose per formulation and one time point 
of sampling post dose. To avoid confounding effects due to 
leukocyte redistribution and trafficking in the days following 
LNP-siRNA administration, we replicated our mouse protocol 
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and  collected  blood  1  hour  post-i.v.  injection  followed  by 
3 days of in vitro culture and analysis of CD45 protein cell 
surface expression. We tested CD45 or luciferase siRNA for-
mulated in KC2 (3 mg/kg) or C12-200 (1 mg/kg) and com-
pared pre- and post injection levels of CD45 expression on 
blood monocytes. In every animal dosed with CD45 siRNA, 
but not with control siRNA, we found CD45 protein reductions 
of ~40–50% (Figure 7a). Encouraged by these results, we 
next monitored organ resident leukocyte silencing in cyno-
molgus macaques. The same doses and formulations were 
used, namely CD45 or luciferase siRNA formulated in KC2 
(3 mg/kg) or C12-200 (1 mg/kg). Three days after injection 
we isolated leukocytes from blood, bone marrow, peritoneal 
cavity, liver, and spleen to compare surface CD45 expres-
sion  in  animals  injected  with  active  versus  control  siRNA. 
We observed 30–60% silencing in liver, blood, spleen, and 
bone marrow-derived cells of monocyte/macrophage lineage   
(n = 3 per group, Figure 7c). Interestingly, peritoneal cav-
ity myeloid cells did not demonstrate any detectable silenc-
ing (Figure 7c). Dot plots from representative animals and 
overlaid histograms from each animal are shown in Supple-
mentary Figure S6, demonstrating that there is a signifi-
cant number of cells with diminished CD45 staining. In this 
experiment, we could not compare pre and post dose levels; 
therefore we analyzed group averages with expected and sig-
nificant variability in nongenetically identical animals. Despite 
this  limitation,  robust  silencing  of  CD45  was  observed  in 
organ resident and blood circulating myeloid cells. It is worth 
mentioning that in cynomolgus macaques we were able to 
detect silencing of CD45 in circulating cells up to 3 days after 
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the injection, which indicates potent and durable silencing in 
the central compartment of myeloid cells ready for recruit-
ment to inflammatory sites.
Discussion
Bringing RNAi-mediated silencing in leukocytes toward 
the clinic. Macrophages are an important therapeutic cel-
lular target in many diseases, but so far developing systemic 
siRNA treatment aimed at these cells has been difficult. In 
this study, we provide evidence that LNP-mediated siRNA 
delivery to macrophages and dendritic cells can be used as 
a robust therapeutic platform. Similar LNP formulations are 
already in clinical trials or in late stage preclinical develop-
ment  for  transthyretin  amyloidosis,  hypercholesterolemia, 
and liver cancer.9
We investigate the ability of two types of liposomal for-
mulations KC2 (an ionizable lipid) and C12-200 (a cationic 
lipid) to mediate silencing in myeloid cells.8 We demonstrate 
dose-dependent silencing for both liposome types with an 
in vivo ED50 of 0.2–0.5 mg. The high in vivo potency of these 
formulations makes them potentially applicable for clinical 
use and is a major improvement on the dose levels used by 
Basha et al. where a 3 mg/kg dose of a KC2-based formula-
tion was employed.21 In the mouse system, systemic delivery 
of LNP-encapsulated siRNA results in silencing in multiple 
cell types (macrophages, dendritic cells, B cells) and ana-
tomic sites (peripheral blood, peritoneal cavity, spleen, bone 
marrow,  liver).  In  tissue  resident  macrophages,  such  as 
those found in the peritoneum, CD45 silencing persists for 
over 2 weeks. We also provide evidence that the observed 
effects on protein levels are mediated by an RNAi mecha-
nism for multiple gene targets. The formulations used in this 
study have a relatively simple composition, containing four 
excipients in addition to the siRNA, and can be manufac-
tured at scale, a crucial attribute for translating LNP-based 
therapies into the clinic.
Silencing of gene targets in rodent myeloid cells had been 
reported by multiple groups using a variety of approaches, 
however translation to higher species has been elusive. Here, 
we  demonstrate  target-specific  silencing  of  CD45  in  liver, 
blood, spleen, and bone marrow derived cells of   monocyte/
macrophage lineage in NHPs for both KC2- and C12-200-
based LNPs. Since silencing of CD45 can be detected in 
circulating myeloid cells 3 days post injection, we have an 
opportunity  for  testing  multiple  formulations  in  NHPs  for 
  further LNP potency improvement. LNPs are highly amena-
ble to attachment of a targeting ligand, as has been recently 
shown for LNP targeting via a GalNAc ligand for hepatocyte 
delivery.8 Targeting LNPs to macrophage surface receptors 
will likely result in an increased cytoplasmic localization of 
the siRNA by increasing the amount of siRNA taken up by 
macro  phages  via  nonphagocytic  pathways  and  may  allow 
further lowering of the therapeutic dose.
To  further  validate  the  therapeutic  potential  of  this  plat-
form we demonstrate that systemic administration of LNP-
  encapsulated  siRNA  targeting  TNFα  results  in  disease 
modifying activity in a mouse model of RA. When compared 
to a previously reported anti-VLA1 antibody treatment, siRNA 
to TNFα gives a similar level of protection in this immune-
inflammatory model. The recent study of Leuschner et al.22 
greatly extends the potential therapeutic applications of this 
platform by demonstrating therapeutic efficacy of anti-CCR2-
specific siRNA delivered using a C12-200 LNP. In this study, 
multiple  rodent  disease  models  are  interrogated,  includ-
ing models of chronic disease.22 The ability to rapidly select 
siRNAs to a gene makes the LNP-siRNA platform a power-
ful tool for rapid validation of therapeutic targets for treating 
inflammation in vivo.
This process can be further aided by the ability to silence 
several independent genes by a cocktail of siRNA as is demon-
strated here. The cocktail approach allows for studying signal-
ing pathways, unraveling nonredundant signals and mimicking 
conditions that are believed to affect whole functional groups 
of  genes.  In  addition,  the  ability  to  simultaneously  silence 
several genes paves the way to therapeutic applications that 
require inhibition of multiple cellular functions.
Delivering  siRNA  to  myeloid  cells  could  provide  novel 
approaches  to  treating  multiple  human  diseases,  such  as 
modulating chronic inflammation in autoimmune disease, pro-
tecting against myeloid-tropic viral infections, reprogramming 
tumor-associated macrophages, restoring functionally insuf-
ficient cells, or killing malignantly transformed immune cells.
Materials and methods
siRNA synthesis and selection. Single-stranded chemically 
modified RNAs were synthesized at Alnylam Pharmaceu-
ticals  (Cambridge,  MA)  using  standard  phosphoramidite 
chemistry. Deprotection and purification of the crude oligo-
ribonucleotides by anion exchange high-performance liquid 
chromatography were carried out according to established 
procedures. siRNAs were generated by annealing equimolar 
amounts of complementary sense and antisense strands. 
CD45- and luciferase-specific siRNA were described earlier,7 
other siRNA used are listed in Supplementary Table S1. 
siRNA specific to murine CD11b was identified by screening 
a set of 28 siRNA duplexes designed to target mouse and rat 
versions of the gene. Best duplexes were selected by trans-
fection of DC2.4 cells and IC50 values determined. siRNA 
specific to β1 integrin and Rab5c were identified similarly 
except NIH3T3 fibroblasts were used for screening. A single 
duplex was selected for each target and synthesized on a 
larger scale for use in LNP preparation.
siRNA formulation in LNPs. LNP siRNA formulations were 
prepared using either of the two recently described novel 
lipids DLin-KC2-DMA4 or C12-200.5 The novel lipids, along 
with  the  colipids  disteroylphosphatidyl  choline,  choles-
terol, and PEG-DMG, were formulated with siRNA using a 
  spontaneous  vesicle  formation  formulation  procedure  as 
  previously  described.4 The  LNPs  had  a  component  molar 
ratio  of  ~50/10/38.5/1.5  (DLin-KC2-DMA  or  C12-200/ 
disteroylphosphatidyl  choline/cholesterol/PEG-DMG).  The 
final lipid:siRNA weight ratio was ~12:1 and 9:1 in the case of 
DLin-KC2-DMA and C12-200 LNPs, respectively. The LNP-
siRNA formulations had mean particle diameters of ~80 nm 
with >90% entrapment efficiency.www.moleculartherapy.org
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In vitro LNP uptake and microscopy. Primary bone marrow-
derived macrophages were isolated using standard methods 
and cultured in glass bottom 96-well plates (Greiner, Frick-
enhausen, Germany). Cells were maintained in Dulbecco’s 
modified Eagle’s medium (Life Technologies, Grand Island, 
NY)  supplemented  with  Penicillin,  Streptomycin,  and  fetal 
bovine  serum.  Cells  were  seeded  for  5  days  in  the  pres-
ence  of  macrophage  colony-stimulating  factor  (8  ng/ml;   
Peprotech,  Rocky  Hill,  NJ),  then  media  was  completely 
renewed for the last overnight culture and KC2 or C12-200 
liposome  formulations  of  Alexa-647  tagged  GFP-targeting 
siRNA (Alnylam Pharmaceuticals), were added for the indi-
cated time points. Cells were counterstained with Hoechst 
without fixation and imaged live. All images were acquired 
using an Opera automated spinning disc confocal system 
(Perkin Elmer, Waltham, MA) and data analyzed using Aca-
pella  Software  (Perkin  Elmer).  Quantification  of  Alexa-647 
labeled  siRNA  uptake  was  determined  by  identifying  the 
number and border of each cell and calculating the number 
of intracellular siRNA positive spots above a predetermined 
minimum intensity threshold. The average number of these 
spots per cell was multiplied by the average intensity value of 
the indentified spots to determine the average siRNA content 
per cell. The average content per cell was averaged across 
20 fields from three replicate wells. In some experiments, pri-
mary macrophages were copulsed with a 1 to 500 dilution 
of a 2% solution of Alexa-488 latex beads (Invitrogen). Per-
centage of colocalization of Alexa-647 siRNA and Alexa-488 
beads was determined by identifying regions of intracellular 
siRNA signal similar to above using Acapella software and 
determining the percent of the total area overlapping with 
AF488 latex bead signal. Similarly, the colocalization percent-
age values were an average of % colocalization of siRNA and 
beads across 20 fields from three replicate wells.
Isolation  of  lymphocytes  from  spleen,  blood,  bone  marrow, 
lymph nodes, peritoneal cavity and liver. Spleens or lymph 
nodes were minced through a nylon mesh (Cell Strainer; BD 
Falcon; BD Biosciences, Franklin Lakes, NJ) to obtain single 
cell suspensions in DMEM, 5% fetal calf serum, and 2 mmol/l 
l-glutamine. Single-cell suspensions were prepared from bone 
marrow by flushing femurs with DMEM (containing 5% fetal 
calf serum).   Erythrocytes were lysed by incubating in lysis buf-
fer (140 mmol/l NH4Cl, 17 mmol/l Tris–HCl, pH 7.65) for 3 min-
utes on ice. Blood was collected in EDTA-containing tubes (BD 
Biosciences – Pharmingen, San Diego, CA). To isolate blood 
lymphocytes, 200 µl of blood was underlaid with Ficoll-Paque 
(GE Healthcare, Piscataway, NJ) and centrifuged at 1,000g at 
room temperature for 20 minutes. Lymphocytes were collected 
from the interface. The peritoneal cavity was washed with 3 
ml of DMEM, 5% fetal calf serum, and 2 mmol/l l-glutamine 
to collect peritoneal leukocytes. Following these procedures, 
lymphocytes were washed twice in DMEM, 5% fetal calf serum 
by 300g centrifugation at 4 °C and resuspended in PBS/BSA/
azide for flow cytometric analysis. Liver lymphocyte isolation 
was done as described earlier.37
Flow cytometry.  Fluorescence staining was performed as 
previously described.38 Antibodies specific for mouse CD45, 
CD19,  CD11b,  CD86,  B220,  MHCII, TCRb    (eBioscience, 
San Diego, CA), or CD11c (BD Biosciences – Pharmingen) 
were used. Antibodies specific for NHP or human (h) hCD31, 
hCD11b,  CD45,  hCD20,  hCD3  (BD  Biosciences  –  Pharmingen) 
or for CD11c (Abcam, Cambridge, MA) were used. Antibodies 
were conjugated to fluorescein isothiocyanate, phycoeryth-
rin,  allophycocyanin  (APC),  phycoerythrin-Cy7,  or  biotin. 
Biotinylated antibodies were detected with streptavidin con-
jugated to fluorescein   isothiocyanate, phycoerythrin, or APC. 
For intracellular staining cells were resuspended in fixation/
permeabilization solution (BD Biosciences – Pharmingen), 
incubated for 20 minute at 4 °C, washed twice with permea-
bilization/wash buffer (BD Biosciences – Pharmingen) and 
stained with TNFα or isotype control Ab (BD Biosciences –   
Pharmingen)  diluted  in  permeabilization/wash  buffer  for 
30 minutes at 4 °C. Stained cells were analyzed using BD 
LSRII (BD   Biosciences – Pharmingen). Analysis was done 
using FlowJo software (Tree Star, Ashland, OR).
Animals. All experiments followed institutional, federal, state and 
local guidelines and were approved by Institutional   Animal Care 
and Use Committee. All the animals were kept in a conventional 
barrier animal facility with a climate-controlled environment hav-
ing 12-hour light/dark cycles in polystyrene cages containing 
wood shavings, fed standard rodent chow and water. Nude mice 
were purchased from COX-7 (Massachusetts General Hospital, 
Boston, MA), C57/BL6 mice from Jackson Labs (Bar Harbor, 
ME). N5RAGE-GFP transgenic mice39 were bred in house as 
homozygous X C57BL/6, heterozygous animals were used for 
experiments. For silencing and distribution experiments mice 
were i.v. bolus injected and sacrificed by CO2 overdose before 
tissue harvest.
NHP experiments were performed with male cynomolgus 
monkeys originating from China, 3–6 years of age, weighing 
4–8 kg. Treatment of the NHPs was conducted by a Charles 
River Laboratories (Wilmington, MA). in accordance with the 
testing facility’s standard operating procedure, which adheres 
to the regulations outlined in the United States Department 
of Agriculture Animal Welfare Act (9 CFR, Parts 1–3) and 
the conditions specified in the Guide for the Care and Use of 
Laboratory   Animals (ILAR publication, 1996, National Acad-
emy Press). On the day of dosing, all monkeys were given 
a single   15-minute i.v. infusion of LNP-formulated siRNAs. 
Blood samples were collected 1 hour predose and 1 hour 
post the end of the infusion and reached Alnylam Pharma-
ceuticals by courier within <2 hours post-collection. In the 
nonterminal study animals were returned to the colony after 
sample collection. In the terminal study, animals were bled 
pre- and post-15 minute i.v. infusion, bone marrow and peri-
toneal  lavage  samples  were  collected  while  the  animal  is 
anesthetized with Nembutal; splenic and liver samples were 
collected post humane sacrifice.
FMT-CT  imaging.  FMT-CT  imaging  is  a  fully  quantitative 
hybrid technique that combines whole body noninvasive fluo-
rescence tomography to determine tissue concentration of 
AF647-tethered siRNA with high-resolution CT imaging for 
exact anatomic location of the siRNA.These imaging stud-
ies  provide  the  biodistribution  of  LNP  siRNA.  Please  see 
  Supplementary  Materials  and  Methods  for  a  detailed 
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Anti-collagen  mAb-induced  arthritis.  Arthrogen-collagen– 
induced arthritis antibody kits were purchased from   Chondrex 
LLC (Redmond, WA), and arthritis was induced using an 
established protocol.40,41 Groups of 10 BALB/c mice (CRL) 
were injected intraperitoneally with a cocktail of five anticol-
lagen type II mAb’s (0.75 mg/animal total, Chondrex, cata-
log #53100) on day 0, followed by intraperitoneal injection 
of 25 µg lipopolysaccharide on day 3. After 3–4 days, the 
mice developed swollen wrists, ankles, and digits. 0.5 mg/  kg 
of siRNA in C12-200 formulation was administered i.v. to 
appropriate groups of mice on day −3, day 0, day +4, and 
day+7. Anti-VLA1 mAb (100 µg; BD Biosciences Pharmin-
gen; catalog #555000) was administered intraperitoneally 
on day 0, 4 hours before arthritogenic Ab cocktail. Severity 
of arthritis in each limb was scored as follows: 0 = normal; 
1 = mild redness, slight   swelling of ankle or wrist; 2 = mod-
erate swelling of ankle or wrist; 3 = severe swelling includ-
ing some digits, ankle, and foot; 4 = maximally inflamed. 
For FMT-CT imaging of   arthritis, animals were injected with 
2 nmol of the pan-cathepsin  protease sensor Prosense-750 
(Perkin Elmer) 24 hours prior FMT imaging.36 FMT imaging 
was done at excitation/emission 750/780 nm for quantitation 
of protease activity. Please see   Supplementary   Materials 
and  Methods  for  a  detailed  description  of  the  FMT-CT 
imaging method.
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